ALD01

ALD01 is a retinal cell therapy developed by Alder Therapeutics for the treatment of Retinitis Pigmentosa (RP), a debilitating inherited blindness disease. It is designed as a mutation-agnostic therapeutic option, meaning it could benefit RP patients regardless of the underlying genetic cause. The therapy utilizes photoreceptor progenitor cells derived from pluripotent stem cells to potentially restore vision or slow disease progression. ALD01 stands out for its promising preclinical data across multiple animal models and features a streamlined, scalable manufacturing process that eliminates animal-derived ingredients and leverages automated 2D culture methods to improve speed and cost-efficiency[1][2][3][6].